AstraZeneca has signed a deal worth up to $1.5 billion with biotechnology company Insitro to use artificial intelligence (AI) to discover new treatments for liver and heart diseases. Announced on October 15, 2026, the partnership will use Insitro’s “Virtual Human” AI platform to study diseases and identify potential targets for new drugs.
The research will focus on metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, and cardiomyopathies, which affect the heart muscle. The deal reflects growing interest in using AI to speed up drug discovery.
AstraZeneca will pay insitro $40 million upfront. Insitro could receive another $1.46 billion if the research meets specific development and sales targets. The deal also includes royalties on future drug sales, meaning the full $1.5 billion will depend on the programmes’ progress and commercial success.
What Is Insitro’s Virtual Human Platform?
Insitro’s Virtual Human platform uses artificial intelligence (AI), machine learning and lab-grown human cells to study how diseases develop. It combines biological data with computer-based analysis to help scientists understand the causes of diseases and identify possible targets for new drugs.
Finding the right drug target is an important step in drug discovery. It helps researchers identify which parts of the body or biological processes a new medicine should affect.
Under the AstraZeneca partnership, Insitro will use the platform to study MASH and cardiomyopathies. Researchers will investigate targets identified by AstraZeneca and work to turn promising findings into potential drug candidates.
The Virtual Human platform is not a complete digital copy of a person. It uses biological models, data and machine learning to study human diseases. Any potential findings will need further testing before they can support the development of new medicines.
ALSO READ: Mark Zuckerberg Bets $1.8 Billion on AI That Could Build Virtual Human Cells
AstraZeneca Turns to AI to Find New Treatments for Liver and Heart Diseases
Developing new medicines can take years, partly because scientists need to understand what causes a disease and how to treat it. AI can help researchers analyse biological data and identify potential drug targets earlier in the research process.
AstraZeneca will use insitro’s AI platform to study MASH and heart muscle diseases. The aim is to identify biological targets that could help researchers develop new treatments for patients with these conditions.
The two companies will share the work. Insitro will use its AI technology and laboratory research to study diseases and identify potential drug candidates. AstraZeneca will handle clinical development and the later stages of bringing successful medicines to market.
The partnership combines Insitro’s expertise in AI and biological research with AstraZeneca’s experience in developing medicines. This could help researchers identify new treatment options for liver and heart diseases.
ALSO READ: AI Is Changing How Scientists Search for Treatments for Brain Diseases
AstraZeneca and Insitro Target Fatty Liver Disease and Heart Conditions
AstraZeneca and Insitro will use AI to identify potential drug targets for two conditions: metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, and cardiomyopathies, which affect the heart muscle.
MASH causes fat buildup, inflammation and liver damage. In severe cases, it can lead to cirrhosis or liver failure. The companies will use AI and human cell models to study the disease and identify possible targets for new treatments.
The research will also examine cardiomyopathies, which can affect the heart’s ability to pump blood and may lead to heart failure. The aim is to understand the biological causes of these conditions and identify potential drug candidates.
The research is still in its early stages. Any potential drugs will need further research and testing before they can be made available to patients.
How AstraZeneca’s $1.5 Billion AI Deal Could Shape Drug Discovery
The $1.5 billion AstraZeneca-insitro deal highlights the growing use of AI in drug discovery. The partnership combines AI analysis with laboratory research to help scientists understand diseases and identify potential targets for new medicines.
The agreement also shows that pharmaceutical companies are investing in biotechnology firms to support early-stage drug research. However, Insitro will receive most of the potential payments only if the research programmes meet specific development and commercial milestones.
The success of the partnership will depend on whether the research identifies promising drug targets and leads to potential treatments. Any resulting drug candidates will still need further development and testing.
The deal reflects AstraZeneca’s investment in AI-based drug discovery, but it remains uncertain whether the research will produce new medicines for liver and heart diseases.
